Examples of using Depocyte in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
DepoCyte is a vial containing a white to off-white-suspension for injection.
DepoCyte should be injected slowly over a period of 1-5 minutes.
See‘ Precautions for the handling and disposal of DepoCyte' below.
DepoCyte must not be administered by any other route of administration.
Adverse reactions more commonly associated with DepoCyte are headache,
Do not mix DepoCyte with any other medicinal products see section 6.2.
An overdose with DepoCyte may be associated with severe arachnoiditis including encephalopathy.
No carcinogenicity, mutagenicity or impairment of fertility studies have been conducted with DepoCyte.
No definite interactions between DepoCyte delivered intrathecally and other medicinal products have been established.
DepoCyte is not recommended for use in children
Just before withdrawing DepoCyte, gently invert the vial to mix the particles evenly.
DepoCyte is a suspension for injection that contains 50 mg of the active substance, cytarabine.
DepoCyte is a sustained-release formulation of cytarabine,
One patient at the 125 mg dose level died of encephalopathy 36 hours after receiving DepoCyte intraventricularly.
Pregnancy and breast-feeding DepoCyte should not be given to pregnant women as it may harm an unborn child.
The importance of concurrent dexamethasone administration should be emphasised at the initiation of each cycle of DepoCyte treatment.
Indicating that the release of cytarabine from DepoCyte and the pharmacokinetics of cytarabine are linear in human CSF.
Before using DepoCyte, warm the vial to room temperature(18°C- 22°C) for at least 30 minutes.
DepoCyte can cause arachnoiditis an inflammation of the arachnoid,
The proportion of patients alive at 12 months was 24% for DepoCyte versus 19% for unencapsulated cytarabine.